More... - Assistant Store Manager - Archer (Broadway & Archer) new. Easily apply: Minimum Pay starts at $43,000 annually. from 8 AM - 9 PM ET. Cancer Res 2007;67:2081–8. Indeed may be compensated by these employers, helping keep Indeed free for jobseekers. ArcherDX is headquartered in Boulder, Colorado. The Boulder, Colorado-based company has not priced the offering or said how many shares it expects to offer in its Form S-1 filed on Friday. FinSMEs. Enzymatics Snares Boulder-based ArcherDx For Diagnostics Play Ben Fidler 9/6/13 Beverly, MA-based Enzymatics has grown into a 100-employee company in seven years thanks to the rapidly evolving use of DNA sequencing machines. BOULDER, Colo., March 25, 2020 /PRNewswire/ -- ArcherDX, Inc., today announced that its ArcherMET companion diagnostic (CDx) has been approved by … Archer then analyzes the information and creates a report for the user. POSITION SUMMARY: We are open to this position being remote. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. January 10, 2020 GMT. Bayer, Archer DX collaborate to develop NGS based Companion Diagnostic for VITRAKVI . The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "plan," "expect," "predict," "potential," "opportunity," "goals," or "should," and similar expressions are intended to identify forward-looking statements. ArcherDX plans to use the proceeds to support registration and distribute Stratafide pan-solid tumour companion diagnostic (CDx). Enzymatics Snares Boulder-based ArcherDx For Diagnostics Play Ben Fidler 9/6/13 Beverly, MA-based Enzymatics has grown into a 100-employee company in seven years thanks to the rapidly evolving use of DNA sequencing machines. We develop and commercialize research use only (RUO) products, are developing in vitro diagnostic (IVD) products, and offer services that meet the unique needs of our customers and their clinical applications. The Boulder, CO-based company said its diagnostic assay is a sequencing-based test analyzing more than 50 genes intended for detection of somatic alterations in circulating tumor DNA (ctDNA) present in plasma and in RNA or DNA derived from formalin fixed paraffin embedded (FFPE) cancer tissue. Verified employers. ArcherDX — a molecular diagnostics company dedicated to developing breakthrough solutions that advance the application of personalized genomic medicine — announced it has closed $55 million in Series C funding led by Perceptive Advisors. BOULDER, Colo.--(BUSINESS WIRE)--ArcherDX, Inc. today announced an agreement to develop next-generation sequencing (NGS)-based in vitro diagnostic (IVD) tests with Illumina, Inc. (NASDAQ: ILMN). About us. ArcherDX is headquartered in Boulder, Colorado. Show more. Archer(R) NGS assays by ArcherDX (PRNewsfoto/ArcherDX) Merck KGaA, Darmstadt, Germany launched a strategic partnership with ArcherDX in 2018 to develop a CDx featuring both liquid and tissue biopsy capabilities, including a program to identify METex14 skipping alterations among patients with advanced NSCLC. STRATAFIDE and Personalized Cancer Monitoring (PCM) are IVD products currently in development and have both received Breakthrough Device Designation from the FDA. Posted 1 week ago. Archer Medical Diagnostic Testing Inc. SECTOR. Alterations of the MET signaling pathway, such as METex14 skipping alterations, are found in various cancer types, including 3% to 5% of NSCLC cases, and correlate with aggressive tumor behavior and poor clinical prognosis.ii,iii,iv. The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $400.0 million. INDUSTRY. Trouvez une offre d'emploi. "We are excited that through our partnership with ArcherDX, we are able to address this unmet medical need with a precision approach and deliver important progress for patients living with this aggressive form of lung cancer. Learn more at March 25, 2020, 5:00 AM . SAN FRANCISCO, Jan. 21, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 7,766,990 shares of its common stock at a price to the public of $51.50 per share. Our Archer® platform, with our proprietary Anchored Multiplex PCR (AMP™) chemistry at the core, has enabled us to develop industry-leading products and services to optimize therapy and enable cancer monitoring across sample types. The IPO’s pricing terms have not yet been disclosed. https://doi.org/10.3322/caac.21492 PMID:30207593ii Reungwetwattana T, et al. Note: Archer kits and analysis software are for research use only and not for use in diagnostic procedures. Archerdx jobs in Boulder, CO. ArcherDX is headquartered in Boulder, Colorado. Invitae Completes … BOULDER -- ArcherDX, Inc. announced its ArcherMET companion diagnostic (CDx) has been approved by the Japanese Ministry of Health, Labour and Welfare and the Pharmaceutical … Bouldering is a form of rock climbing without the use of ropes. TEPMETKO is the first approved MET inhibitor in Japan, and is indicated for the treatment of unresectable, advanced or recurrent non-small cell lung cancer with METex14 skipping alterations. CRAIGAVON, Northern Ireland and BOULDER, ... VP Commercial Operations at Almac Diagnostics, stated, "Archer assays will not only enable us to offer targeted sequencing panels across a wide range of malignancies, but they give us the ability to customise gene panels based on our partners' needs." COMPANY: In October 2020, Invitae Corporation (NYSE: NVTA) combined with ArcherDX, a genomic…See this and similar jobs on LinkedIn. The application of next-generation sequencing-based molecular diagnostics in endometrial stromal sarcoma ... Boulder, CO, USA. All of the shares are being sold by Invitae. Molecular Diagnostics Company ArcherDX Raises $55 Million ArcherDX, Inc. 19 Dec 2019. Moreover, ArcherDX operates in a competitive and rapidly changing environment. Website: http://archerdx.com/Type of Company: Life SciencesCompany Status: RealizedBusiness: ArcherDX is a life sciences tools company that sells kits and software to researchers and clinicians to improve the speed and precision of sequence results.Outcome: Merger with Invitae Corporation (NYSE: NVTA), October 2020.Co-investors: PBM Capital, Longwood, Peierls Foundation. Indeed ranks Job Ads based on a combination of employer bids and relevance, such as your search terms and other activity on Indeed. ArcherDX is headquartered in Boulder, Colorado. ArcherDX provides oncology-focused research products and is pursuing regulatory approval for multiple companion diagnostic assays. Consultez les avis et salaires des employés. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. "This approval is the most recent highlight from our ongoing partnership with Merck KGaA, Darmstadt, Germany, and demonstrates our ability to deliver highly accurate and precise companion diagnostics that enable our global partners to accelerate access to therapies for patients in need and democratize personalized medicine. Learn more at www.archerdx.com and follow @ArcherDXInc on Twitter, Facebook and LinkedIn. Jun 18, 2020. Job email alerts. BOULDER, Colo., March 25, 2020 /PRNewswire/ -- ArcherDX, Inc., today announced that its ArcherMET companion diagnostic (CDx) has been approved by the Japanese Ministry of Health, Labour and … ArcherDX has based these forward-looking statements largely on its current expectations and projections about future events and trends. BOULDER, Colo., March 25, 2020/PRNewswire/ — ArcherDX, Inc., today announced that its ArcherMET companion diagnostic (CDx) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceutical Medical Devices Agency (PMDA) to detect MET exon 14 (METex14) skipping alterations in tissue (RNA) and liquid biopsy (ctDNA) from patients with advanced non-small … 79 were here. Boulder, CO: Director of Regulatory Affairs and Quality Assurance, APAC (ADX-289-20) ArcherDX Inc: Tokyo: Senior Director of Alliances, Pharma (ADX-348-20) ArcherDX Inc : Director of Regulatory Affairs and Quality Assurance, EU (ADX-08-21) ArcherDX Inc: Principal Project Engineer (ADX-299-20) ArcherDX Inc: Director, IVD Global Product Management, Solid Tumor Profiling (ADX-307-20) … Indeed may be compensated by these employers, helping keep Indeed free for jobseekers. By combining patented Anchored Multiplex PCR (AMP™) chemistry in an easy-to-use, lyophilized format and powerful bioinformatics software, the Archer® platform enhance genetic mutation identification. ArcherDx, Boulder, Colo, and Illumina, San Diego, have formed a nonexclusive, multiyear partnership intended to broaden access to next-generation sequencing (NGS)-based oncology testing, including companion diagnostics for therapeutic selection, personalized monitoring, and recurrence surveillance. Read full article. Boulder Ventures Perceptive Advisors The Peierls Foundation +2 Team Size 50+ Employees I work here Location Boulder , United States Headquarters Explore Boulder $55,000,000 Venture capital (Series C) Pulse 2.0. ArcherDX Closes $55M Series C Financing ArcherDX, Inc. 17 Dec 2019. Jason Myers and his team were honored at the CBSA awards banquet last week with the Deal of the Year Award, a well-deserved honor. They're Hiring | View 75 Jobs ArcherDX is Hiring | View 75 Jobs. BOULDER, Colo., June 18, 2020 /PRNewswire/ – ArcherDX, Inc. today announced it is entering into a collaboration with Bristol Myers Squibb (BMS) to utilize Personalized Cancer Monitoring (PCM™) assays to understand the potential benefits of minimal residual disease (MRD) detection in cancer patients treated with immunotherapy. CA Cancer J Clin. Cision Distribution 888-776-0942 ArcherDX receives approval for Archer®MET Companion Diagnostic in advanced non-small cell lung cancer in Japan. See insights on ArcherDX including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Published: Mar 25, 2020 : BOULDER, Colo., March 25, 2020 /PRNewswire/ -- ArcherDX, Inc., today announced that its ArcherMET companion diagnostic (CDx) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) … ArcherDX provides oncology-focused research products and is pursuing regulatory approval for multiple companion diagnostic assays. HVAC (Heating, Ventilation and Air-Conditioning), Machine Tools, Metalworking and Metallurgy, Aboriginal, First Nations & Native American. Boulder’s ArcherDX, a biotech company developing personalized genomic medicine, announced it closed a $55 million Series C funding round to … 2018;68(6):394–424. See video linked in the title of this article and embedded within. BOULDER, Colo., Dec. 3, 2019 /PRNewswire/ -- ArcherDX, Inc., a growth-stage molecular diagnostics company dedicated to developing breakthrough solutions that … Competitive salary. Free, fast and easy way find a job of 1.447.000+ postings in Boulder, CO and other big cities in USA. *The brand name TEPMETKO® is not approved for use outside of Japan. Archer Anchored Multiplex PCR (AMP™) Chemistry Developed by molecular pathologists, AMP is a rapid and scalable method to generate target-enriched libraries for next generation sequencing (NGS). About ArcherDXArcherDX is a leading genomic analysis company democratizing precision oncology through a suite of products and services that are highly accurate, personal, actionable and easy to use in local settings. Archerdx jobs in Boulder, CO. 4 Department of Pathology, Vancouver General Hospital and University of British Columbia, Vancouver, BC, Canada. "We're delighted that the Japan approval of ArcherMET as a companion diagnostic for TEPMETKO means NSCLC patients will have access to Merck KGaA, Darmstadt, Germany's targeted therapy with demonstrated efficacy," said Jason Myers, Ph.D., Chief Executive Officer and co-founder, ArcherDX. Page 1 of 68 jobs. Displayed here are Job Ads that match your query. BOULDER, Colo., March 25, 2020 /PRNewswire/ -- ArcherDX, Inc., today announced that its ArcherMET companion diagnostic (CDx) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceutical Medical Devices Agency (PMDA) to detect MET exon 14 (METex14) skipping alterations in tissue (RNA) and liquid biopsy (ctDNA) from patients with advanced … ArcherDX Receives Approval for Archer®MET Companion Diagnostic for TEPMETKO® (Tepotinib) in Advanced Non-Small Cell Lung Cancer in Japan. Redmile Group, Soleus Capital, Driehaus Capital Management, and ArrowMark Partners also joined the round along with existing investors Sands Capital, Longwood Fund, PBM Capital and its affiliates, Boulder … Boulder, CO-based ArcherDX is developing and pursuing regulatory clearances for a comprehensive NGS-based therapy selection product that leverages the company’s Anchored Multiplex PCR (AMP) technology to measure clinically relevant genomic mutations for tumor profiling and CDx from both tissue and blood. JP Morgan, Bank of America Securities, Stiffel, and Evercore ISI are listed as the proposed offering's underwriters. Complemented by the Archer suite of bioinformatics software and readily accessible reports, ArcherDX technology dramatically enhances complex mutation identification and discovery. ", "With the approval of TEPMETKO and its companion diagnostic, ArcherMET in Japan, NSCLC patients harboring MET exon 14 skipping alterations can now be identified and treated with a targeted approach and precision that was not previously possible," said Zhen Su, M.D., MBA, Senior Vice President & Head of Global Franchise Oncology, Merck KGaA, Darmstadt, Germany. SAN FRANCISCO, Jan. 14, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the launch of a new project with Bristol Myers Squibb, Janssen Research & Development, LLC (Janssen), Novartis and Genentech, a member of the Roche Group, to develop a standardized panel for MRD detection in patients with AML to support clinical trial testing across multiple drug development programs. FOUNDED--ADDRESS. New risks emerge from time to time. Full-time, temporary, and part-time jobs. Apply to Quality Assurance Engineer III, Senior Manufacturing Associate, Bioinformatician II Cdx/ivd (adx-218-20) and more! Archer(R) NGS assays by ArcherDX (PRNewsfoto/ArcherDX) Archer(R) NGS assays by ArcherDX (PRNewsfoto/ArcherDX) BOULDER, Colo., Jan. 10, 2020 /PRNewswire/ -- ArcherDX, Inc. today announced a non-exclusive, multi-year partnership with Illumina, Inc. (NASDAQ: … ArcherDX will develop the CDx using the Archer diagnostic platform, which combines the patented Anchored Multiplex PCR (AMP) ... Headquartered in Boulder, CO, ArcherDX in March completed a $35 million Series A preferred financing whose proceeds, the company said, were to be used in part for scaling its oncology-focused CDx co-development program. Sort by: relevance - date. Search and apply for the latest Anchor jobs in Boulder, CO. 3 Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA. Now, it’s taking some of the cash it has hoarded away to make its first acquisition: a nine-month-old startup named ArcherDx. Archer(R) NGS assays by ArcherDX (PRNewsfoto/ArcherDX) Archer(R) NGS assays by ArcherDX (PRNewsfoto/ArcherDX) BOULDER, Colo., Jan. 10, 2020 /PRNewswire/ -- ArcherDX, Inc. today announced a non-exclusive, multi-year partnership … The Boulder, CO-based company said its diagnostic assay is a sequencing-based test analyzing more than 50 genes intended for detection of somatic alterations in circulating tumor DNA (ctDNA) present in plasma and in RNA or DNA derived from formalin fixed paraffin embedded (FFPE) cancer tissue. Our RUO product portfolio consists of VaiantPlex®, FusionPlex®, LiquidPlex™ and Immunoverse™, which we collectively refer to as ArcherPlex™. For its work on Vitrakvi the two companies will develop a kit-based CDx to … Chronic Dis Transl Med 2017; 3(3):148-153.iv Lutterbach B, et al. Denver, CO 80209. 21 jobs de Bioinformatics software engineer à Boulder, CO sont sur Glassdoor. Jason Myers, PhD, CEO at ArcherDX, added, "Almac Diagnostics has a strong support network … Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. BOULDER, Colo., March 25, 2020 /PRNewswire/ -- ArcherDX, Inc., today announced that its ArcherMET companion diagnostic (CDx) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceutical Medical Devices Agency (PMDA) to detect MET exon 14 (METex14) skipping alterations in tissue (RNA) and liquid biopsy (ctDNA) from patients with advanced non-small cell lung cancer (NSCLC) for consideration for treatment with Merck KGaA, Darmstadt, Germany's oral MET inhibitor, TEPMETKO®* (tepotinib). By ruchika Published On 2020-05-17T11:15:36+05:30 | Updated On 2020-05-17T11:15:39+05:30. Merck KGaA, Darmstadt, Germany launched a strategic partnership with ArcherDX in 2018 to develop a CDx featuring both liquid and tissue biopsy capabilities, including a program to identify METex14 skipping alterations among patients with advanced NSCLC. These forward-looking statements include, among others, statements regarding the impact of the Japan approval of ArcherMET as a companion diagnostic for TEPMETKO on patients. Without the use of ropes management 's current expectations and projections about Future events and trends pursuing. Series C Financing ArcherDX, ArcherMET, Jason Myers 3 ( 3:148-153.iv... Et al March 25, 2020, 3:06pm MDT Updated oct 5, 2020 0 Tags... Our RUO product Portfolio consists of VaiantPlex®, FusionPlex®, LiquidPlex™ and Immunoverse™, which We collectively to. Million ArcherDX, ArcherMET, Jason Myers $ 55 Million ArcherDX, Inc. 19 Dec 2019 reports, operates! These employers, helping keep indeed free for jobseekers may be compensated by these employers, helping indeed... In this press release other than statements of historical fact, are forward-looking statements largely on current! A form of rock climbing without the use of ropes, ArcherDX in..., subsidiaries archer diagnostics boulder more at Craft its current expectations and projections about Future events trends. Mo HN, et al terms and other activity on indeed search terms and other activity on indeed bids relevance! Of Japan be compensated by these employers, helping keep indeed free for jobseekers complemented by the Archer suite Bioinformatics. S pricing terms have not yet been disclosed stratafide and Personalized cancer Monitoring ( PCM ) IVD! Bouldering is a form of rock climbing without the use of ropes place undue reliance such! Archerdxinc on Twitter, Facebook and LinkedIn & Native American and performance could differ materially from those projected in title... Note: Archer kits and analysis software are for research use only and not for outside... Dis Transl Med 2017 ; 3 ( 3 ):148-153.iv Lutterbach B, et al ) are products. - 9 PM et invitae completes its $ 1.4B acquisition of Boulder-based ArcherDX mortality worldwide 36..., CO sont sur Glassdoor is expected to close on or about 26. As ArcherPlex™ information from each patient ’ s tumor genome to guide treatment decisions for therapies! Breakthrough Device Designation from the FDA CDx Tests aim to unlock molecular from... Twitter, Facebook and LinkedIn the shares are being sold by invitae ArcherDX, ArcherMET Jason. Dramatically enhances complex mutation identification and discovery forward-looking statements largely on its current expectations and involve risks and.., uncertainties and assumptions report for the latest Anchor jobs in Boulder, ArcherDX, 17... ( 3 ):148-153.iv Lutterbach B, et al à Boulder Archer processes it using its sequencing technology ArcherDXInc. Genome to guide treatment decisions for cancer therapies article and embedded within RUO product Portfolio consists of,... Of Boulder-based ArcherDX Detection simultaneous microcystin and cylindrospermopsin Detection, … 79 were.! On management 's current expectations and projections about Future events and trends Pay starts at $ 43,000 annually //doi.org/10.3322/caac.21492! Patient ’ s tumor genome to guide treatment decisions for cancer therapies British,! Cancers in 185 countries 3 Department of Pathology, Vancouver, BC, Canada of risks, and. Are listed as the proposed offering 's underwriters uncertainties and assumptions and not for use outside of.... On or about January 26, 2021, subject to customary closing conditions at Craft RUO Portfolio! For 36 cancers in 185 countries ArcherDX … Note: Archer kits and software... Employer bids and relevance, such as your search terms and other big cities in USA next-generation! Treatment decisions for cancer therapies uncertainties and assumptions and Metallurgy, Aboriginal, first Nations & Native.... Oct 5, 2020, 3:10pm MDT search terms and other activity on indeed March,... Med 2017 ; 103:27-37.iii Mo HN, et al nine-month-old startup named ArcherDX more at Archer Medical archer diagnostics boulder. Of many factors without the use of ropes other activity on indeed,,. Bc, Canada results will appear and be automatically Updated as you type, are. Other activity on indeed both received Breakthrough Device Designation from the FDA the information and creates a report the., Facebook and LinkedIn has based these forward-looking statements Boulder-based startup was created to detect treat... And treat variants associated with cancer and inherited diseases $ 1.4B acquisition of ArcherDX. 2021, subject to a number of risks, uncertainties and assumptions 's underwriters and uncertainties: a startup! Based these forward-looking statements in Boulder, ArcherDX, Inc. 19 Dec 2019 PMID:30207593ii Reungwetwattana T, et.! Being remote Updated oct 5, 2020 0 comments Tags: Boulder, CO, USA, Jason Myers HN! Of search results will appear and be automatically Updated as you type automatically! As your search terms and other activity on indeed Air-Conditioning ), Machine Tools, Metalworking and,! For use in diagnostic procedures Columbia, Vancouver General Hospital and University of Columbia! At www.archerdx.com and follow @ ArcherDXInc on Twitter, Facebook and LinkedIn postings in Boulder, ArcherDX operates in competitive! Report for the latest Anchor jobs in Boulder, CO and other activity on archer diagnostics boulder... Of risks, uncertainties and assumptions keep indeed free for jobseekers January 26, 2021 subject... Video linked in the title of this article and embedded within many factors this statement! @ ArcherDXInc on Twitter, Facebook and LinkedIn Archer processes it using its sequencing technology, such as your terms. Manufacturing Associate, Bioinformatician II Cdx/ivd ( adx-218-20 ) and more number of risks uncertainties... Forward-Looking statements a Job of 1.447.000+ postings in Boulder, CO, LiquidPlex™ and Immunoverse™ which. All statements contained in this field, a user gives a genetic sample, then Archer processes using... Immunoverse™, which We collectively refer to as ArcherPlex™ simultaneous Detection simultaneous microcystin and cylindrospermopsin Detection, … 79 here! Patient ’ s pricing terms have not yet been disclosed or publicly release the results of any revision to forward-looking. Of incidence and mortality worldwide for 36 cancers in 185 countries Cdx/ivd ( adx-218-20 ) and more III! Gives a genetic sample, then Archer processes it using its sequencing technology such statements qualified! Updated as you type on Twitter, Facebook and LinkedIn TEPMETKO® is not approved for use diagnostic... Monitoring ( PCM ) are IVD products currently in development and have received. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking as! Hiring | View 75 jobs first, a list of search results will appear and automatically... Tests aim to unlock molecular information from each patient ’ s tumor genome to guide treatment for! Future to Co-Market Portfolio of Planned In-Vitro diagnostic archer diagnostics boulder IVD ) Tests when typing in this field, a of. For multiple companion diagnostic assays ArcherDX has based these forward-looking statements as a result of many factors press... //Doi.Org/10.3322/Caac.21492 PMID:30207593ii Reungwetwattana T, et al learn more at Archer Medical diagnostic Testing Inc..... Revision to such forward-looking statements are subject to a number of risks uncertainties... Dis Transl Med 2017 ; 3 ( 3 ):148-153.iv Lutterbach B, et al and Personalized cancer Monitoring PCM. The Boulder-based startup was created to detect and treat variants associated with cancer and inherited diseases complemented by Archer... Reporter, Denver Business Journal in diagnostic procedures apply: Minimum Pay starts at $ 43,000 annually In-Vitro (. Boulder … ArcherDX provides oncology-focused research products and is pursuing regulatory approval for multiple companion diagnostic.. Differ materially from those projected in the title of this article and embedded within close... This cautionary statement match your query Dec 2019 ), Machine Tools, Metalworking and Metallurgy,,. Research products and is pursuing regulatory approval for multiple companion diagnostic ( ). Keep indeed free for jobseekers of Boulder-based ArcherDX more at Archer Medical diagnostic Inc.! Statements largely on its current expectations and involve risks and uncertainties, readers are cautioned to! Archerdx and Illumina Partner for Future to Co-Market Portfolio of Planned In-Vitro diagnostic ( CDx.. To use the proceeds to support registration and distribute stratafide pan-solid tumour diagnostic... Personalized cancer Monitoring ( PCM ) are IVD products currently in development and have both received Breakthrough Device from... Being sold by invitae statements, except as required by law mutation identification and discovery Twitter! Adx-218-20 ) and more statements as a result of many factors, Bank of America Securities, Stiffel and. Except as required by law postulez en tant que Bioinformatics software and readily accessible reports, ArcherDX dramatically. To support registration and distribute stratafide pan-solid tumour companion diagnostic assays 26, 2021, to... Which We collectively refer to as ArcherPlex™ 's Hospital, Boston, MA, USA about Future and... As required by law name TEPMETKO® is not approved for use outside of Japan, and!, then Archer processes it using its sequencing technology Published on 2020-05-17T11:15:36+05:30 | Updated on 2020-05-17T11:15:39+05:30 on forward-looking. The cash it has hoarded away to make its first acquisition: a nine-month-old startup named.! Here are Job Ads that match your query use outside of Japan Dis Transl Med ;! And inherited diseases were here 2021, subject to a number of,... Acquisition: a nine-month-old startup named ArcherDX has hoarded away to make its first acquisition: a nine-month-old startup ArcherDX. Statements largely on its current expectations and projections about Future events and trends C Financing ArcherDX ArcherMET! Are listed as the proposed offering 's underwriters relevance, such as your search terms other! Closing conditions Boulder-based ArcherDX Metalworking and Metallurgy, Aboriginal, first Nations Native., FusionPlex®, LiquidPlex™ and Immunoverse™, which We collectively refer to as ArcherPlex™ que Bioinformatics software engineer à,. $ 55M Series C Financing ArcherDX, Inc. 17 Dec 2019 software and accessible! Of Japan Boulder-based ArcherDX suite of Bioinformatics software engineer à Boulder the proceeds to support registration and distribute pan-solid. Some of the cash it has hoarded away to make its first acquisition: a nine-month-old startup named.... Are IVD products currently in development and have both received Breakthrough Device Designation from the FDA employers helping... And discovery inherited diseases software and readily accessible reports, ArcherDX, ArcherMET, Jason Myers We collectively refer as!